We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Lonza and Singapore's Bio*One Capital have entered into a joint venture, Lonza Biologics Tuas, to build a large-scale mammalian cell-culture facility in Singapore for the manufacture of commercial biopharmaceuticals.
Most HIV-positive people in Africa still lack access to important antiretroviral (ARV) drugs five after a World Trade Organization enacted a declaration to allow developing nations to make generic copies of brand drugs, the UN Integrated Regional Information Networks (IRIN) reports.
Siga Technologies announced it has made a presentation to the World Health Organization's (WHO) Smallpox Advisory Committee on Variola Virus Research on the progress of SIGA-246.
Eisai has informed the UK's National Institute for Health and Clinical Excellence (NICE) that the company, along with Pfizer, plans to apply for a judicial review of NICE's decision on the companies' drug Aricept.
Indian pharmaceutical company Advinus Therapeutics and Merck have announced they have formed a drug discovery and clinical development collaboration in the area of metabolic disorders.
Iraq's Ministry of Health has begun a five-day national polio immunization campaign to protect 4.8 million Iraqi children after security problems delayed it for weeks, the UN Integrated Regional Information Networks (IRIN) reports.
Merck announced that a federal court jury in New Orleans found in favor of Merck, rejecting a claim that Vioxx caused the 2003 heart attack of a then 61-year-old Utah man.
The World Health Organization (WHO) and more than 20 international partners have launched a plan to help national authorities safeguard their populations from counterfeit medicines.
Zydus Cadila has filed an investigational new drug (IND) application for a new molecular entity -- ZYO1, a new drug candidate for treating obesity and related disorders -- with the Drugs Controller General (DCGI) of India.
Israeli drugmaker Teva Pharmaceutical Industries announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a May 1 decision by a district court awarding the company 180-day exclusivity for its generic version of Merck's Zocor (simvastatin) tablets.